Amerikanische Gesellschaft für Hirudotherapie

Anticoagulation for prosthetic heart valves during pregnancy: is low-molecular-weight heparin an alternative?.

Research article published in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2002)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportKlinische StudienLeyh et al. · European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2002

Abstract

We report on the treatment failure of low molecular weight heparin (LMWH) for anticoagulation in a pregnant woman that underwent artificial mitral valve replacement 10 years prior to her pregnancy. Until she became pregnant warfarin was administered for anticoagulation, but due to the often mentioned increased risk for warfarin-induced maternal and fetal complications, at gestational week 5 the anticoagulation regimen was switched to subcutaneous application of low molecular weight heparin. At gestational week 24 our patient developed acute life-threatening pulmonary edema and hemodynamic instability due to acute mitral valve thrombosis and underwent emergency valve re-replacement with a biological porcine valve. She recovered uneventfully and gave birth to a healthy child at gestational week 35. In addition to our case presentation we review the sparse evidence in the literature regarding anticoagulation in pregnant women with mechanical heart valves and discuss the rational of different anticoagulation regimens with regards to maternal and fetal outcome. Special consideration is directed towards LMWH administration as an alternative to oral anticoagulation during pregnancy in women with mechanical heart valves.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal ArticleReview
Indexed MeSH termsAdultAnticoagulantsFemaleHeart Valve ProsthesisHeparin, Low-Molecular-WeightHumansMitral ValvePregnancyPregnancy Complications, HematologicThrombosisWarfarin

Zusammenfassung

Anticoagulation for prosthetic heart valves during pregnancy: is low-molecular-weight heparin an alternative?.

Warum dies für die Hirudotherapie relevant ist

This case report describes treatment failure of low-molecular-weight heparin for anticoagulation in a pregnant woman with a mechanical mitral valve prosthesis, who developed acute valve thrombosis at gestational week 24 requiring emergency valve re-replacement, and reviews anticoagulation options for pregnant women with mechanical heart valves. The abstract contains no mention of leeches, hirudin, or any leech-derived therapeutic. Therefore, this article has no defensible relevance to hirudotherapy or the leech secretome.

Zitation

Anticoagulation for prosthetic heart valves during pregnancy: is low-molecular-weight heparin an alternative?.

Leyh et al. · European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2002

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.